A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia.

A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia.

In chronic myeloid leukemia (CML) patients, 3-month BCR-ABL1 levels have consistently been correlated with further outcomes. Monitoring molecular responses in CML using the GeneXpert (Cepheid) platform has shown an optimal correlation with standardized RQ-PCR (IS) when measuring BCR-ABL1 levels lowe...

Full description

Bibliographic Details
Main Authors: Valentín García-Gutiérrez, María T Gómez-Casares, José M Puerta, Juan M Alonso-Domínguez, Santiago Osorio, Juan C Hernández-Boluda, Rosa Collado, María J Ramírez, Fátima Ibáñez, María L Martín, Juan D Rodríguez-Gambarte, Carolina Martínez-Laperche, Montse Gómez, Dolly V Fiallo, Sara Redondo, Alicia Rodríguez, Concepción Ruiz-Nuño, Juan L Steegmann, Antonio Jiménez-Velasco, Spanish Group of Chronic Myeloid Leukemia (GELMC)
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5344481?pdf=render

Internet

http://europepmc.org/articles/PMC5344481?pdf=render

Similar Items